LICENSE AGREEMENTLicense Agreement • August 23rd, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • California
This License Agreement (the “Agreement”) is effective as of April 4, 2018 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and IMMUNOMEDICS, INC., a Delaware corporation (“Licensee”), each located at the respective address set forth in Section 13.15 below, with respect to the facts set forth below.
LETTER AGREEMENT FOR THE COMMERCIAL MANUFACTURING OF IMMU- 132 PRODUCTConfidential Treatment • August 23rd, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
This Letter of Intent (this “LOI”) is entered into between Immunomedics, Inc., a corporation with its principal office located at 300 The American Road Morris Plains, NJ 07950, USA (“Immunomedics”), and BSP Pharmaceuticals S.p.A., having a place of business at via Appia km 65,561 04013 Latina Scalo (LT), Italy (“BSP”), effective as of February 26, 2018 (the “Effective Date”).
